These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

284 related articles for article (PubMed ID: 24075603)

  • 41. Item response analysis of the Positive and Negative Syndrome Scale.
    Santor DA; Ascher-Svanum H; Lindenmayer JP; Obenchain RL
    BMC Psychiatry; 2007 Nov; 7():66. PubMed ID: 18005449
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Effects of olanzapine long-acting injection on levels of functioning among acutely ill patients with schizophrenia.
    Witte MM; Case MG; Schuh KJ; Ascher-Svanum H
    Curr Med Res Opin; 2012 Mar; 28(3):315-23. PubMed ID: 22236137
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Pimavanserin for negative symptoms of schizophrenia: results from the ADVANCE phase 2 randomised, placebo-controlled trial in North America and Europe.
    Bugarski-Kirola D; Arango C; Fava M; Nasrallah H; Liu IY; Abbs B; Stankovic S
    Lancet Psychiatry; 2022 Jan; 9(1):46-58. PubMed ID: 34861170
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Olanzapine versus placebo in adolescents with schizophrenia: a 6-week, randomized, double-blind, placebo-controlled trial.
    Kryzhanovskaya L; Schulz SC; McDougle C; Frazier J; Dittmann R; Robertson-Plouch C; Bauer T; Xu W; Wang W; Carlson J; Tohen M
    J Am Acad Child Adolesc Psychiatry; 2009 Jan; 48(1):60-70. PubMed ID: 19057413
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Fasting insulin serum levels and psychopathology profiles in male schizophrenic inpatients treated with olanzapine or risperidone.
    Konarzewska B; Waszkiewicz N; Galińska B; Szulc A
    Neuro Endocrinol Lett; 2013; 34(4):322-8. PubMed ID: 23803867
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Asenapine in the treatment of negative symptoms of schizophrenia: clinical trial design and rationale.
    Alphs L; Panagides J; Lancaster S
    Psychopharmacol Bull; 2007; 40(2):41-53. PubMed ID: 17514185
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Risperidone and olanzapine versus another first generation antipsychotic in patients with schizophrenia inadequately responsive to first generation antipsychotics.
    Chen JJ; Chan HY; Chen CH; Gau SS; Hwu HG
    Pharmacopsychiatry; 2012 Mar; 45(2):64-71. PubMed ID: 22086749
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Efficacy and tolerability of ziprasidone versus risperidone in patients with acute exacerbation of schizophrenia or schizoaffective disorder: an 8-week, double-blind, multicenter trial.
    Addington DE; Pantelis C; Dineen M; Benattia I; Romano SJ
    J Clin Psychiatry; 2004 Dec; 65(12):1624-33. PubMed ID: 15641867
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Divalproex ER combined with olanzapine or risperidone for treatment of acute exacerbations of schizophrenia.
    Casey DE; Daniel DG; Tamminga C; Kane JM; Tran-Johnson T; Wozniak P; Abi-Saab W; Baker J; Redden L; Greco N; Saltarelli M
    Neuropsychopharmacology; 2009 Apr; 34(5):1330-8. PubMed ID: 19052541
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Olanzapine versus flupenthixol in the treatment of inpatients with schizophrenia: a randomized double-blind trial.
    Gattaz WF; Diehl A; Geuppert MS; Hubrich P; Schmitt A; Linde I; Maras A; Dittmann RW
    Pharmacopsychiatry; 2004 Nov; 37(6):279-85. PubMed ID: 15551194
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Pomaglumetad methionil: no significant difference as an adjunctive treatment for patients with prominent negative symptoms of schizophrenia compared to placebo.
    Stauffer VL; Millen BA; Andersen S; Kinon BJ; Lagrandeur L; Lindenmayer JP; Gomez JC
    Schizophr Res; 2013 Nov; 150(2-3):434-41. PubMed ID: 24035403
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Efficacy and Safety of Asenapine Versus Olanzapine in Combination With Divalproex for Acute Mania: A Randomized Controlled Trial.
    Mahajan V; Arora M; Tandon VR; Gillani Z; Praharaj SK
    J Clin Psychopharmacol; 2019; 39(4):305-311. PubMed ID: 31205195
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Early improvement on antipsychotic treatment as a predictor of subsequent response in schizophrenia: analyses from ziprasidone clinical studies.
    O'Gorman C; Kapur S; Kolluri S; Kane J
    Hum Psychopharmacol; 2011; 26(4-5):282-90. PubMed ID: 21638329
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Ziprasidone and amisulpride effectively treat negative symptoms of schizophrenia: results of a 12-week, double-blind study.
    Olié JP; Spina E; Murray S; Yang R
    Int Clin Psychopharmacol; 2006 May; 21(3):143-51. PubMed ID: 16528136
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A double-blind, randomized, placebo-controlled study with JNJ-37822681, a novel, highly selective, fast dissociating D₂ receptor antagonist in the treatment of acute exacerbation of schizophrenia.
    Schmidt ME; Kent JM; Daly E; Janssens L; Van Osselaer N; Hüsken G; Anghelescu IG; Van Nueten L
    Eur Neuropsychopharmacol; 2012 Oct; 22(10):721-33. PubMed ID: 22464973
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Efficacy of Low-dose Olanzapine in Combination with Sertraline on Negative Symptoms and Psychosocial Functioning in Schizophrenia: A Randomized Controlled Trial.
    Xiu M; Zhao L; Sun Q; Lang X
    Curr Neuropharmacol; 2024; 22(8):1406-1413. PubMed ID: 37711125
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Initial severity of schizophrenia and efficacy of antipsychotics: participant-level meta-analysis of 6 placebo-controlled studies.
    Furukawa TA; Levine SZ; Tanaka S; Goldberg Y; Samara M; Davis JM; Cipriani A; Leucht S
    JAMA Psychiatry; 2015 Jan; 72(1):14-21. PubMed ID: 25372935
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The heterogeneity of antipsychotic response in the treatment of schizophrenia.
    Case M; Stauffer VL; Ascher-Svanum H; Conley R; Kapur S; Kane JM; Kollack-Walker S; Jacob J; Kinon BJ
    Psychol Med; 2011 Jun; 41(6):1291-300. PubMed ID: 20925971
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A randomized double-blind study of risperidone and olanzapine in the treatment of schizophrenia or schizoaffective disorder.
    Conley RR; Mahmoud R
    Am J Psychiatry; 2001 May; 158(5):765-74. PubMed ID: 11329400
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Associations among obesity, acute weight gain, and response to treatment with olanzapine in adolescent schizophrenia.
    Kemp DE; Correll CU; Tohen M; Delbello MP; Ganocy SJ; Findling RL; Chang K
    J Child Adolesc Psychopharmacol; 2013 Oct; 23(8):522-30. PubMed ID: 24111982
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.